Metagenomic Next-Generation Sequencing Improves Pathogen Detection and Rational Use in Patients with Infectious Fever: A Retrospective Study
This retrospective study demonstrates that metagenomic next-generation sequencing (mNGS) significantly outperforms conventional microbiological tests in detecting pathogens, particularly rare and atypical organisms, in patients with infectious fever, thereby guiding more rational antibiotic use especially in cases with elevated procalcitonin levels or prior antibiotic exposure.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Fever is one of the body's most ancient and universal alarms, a signal that something is wrong deep within. For doctors, the challenge is not just to lower the temperature, but to find the invisible invader causing the heat. Is it a common bacterium, a stubborn fungus, or a rare virus that few have ever seen? Traditionally, finding the culprit has relied on growing the organism in a lab dish, a process that can take days or even weeks, and often fails if the germ is difficult to grow or if the patient has already taken antibiotics that stop the bacteria from multiplying. In recent years, a new tool has emerged that reads the genetic code of all the microbes in a sample at once, looking for any match in a massive digital library. This method, known as metagenomic next-generation sequencing, promises to see what traditional tests miss, but doctors need to know exactly when to use it, which samples to test, and whether it truly changes how they treat patients.
A team of researchers at the Third Affiliated Hospital of Sun Yat-sen University in China set out to test this new tool against the old standards in a real-world hospital setting. They looked back at the medical records of 125 patients who had been admitted with unexplained fevers and suspected infections. Every single one of these patients had undergone both the traditional tests and the new genetic sequencing. The goal was to see which method found the actual cause of the illness more often and to understand how the results influenced the doctors' decisions. The study focused on a group of patients where the situation was often complicated; more than four out of five of them had already received antibiotics before the samples were taken, a scenario that typically makes it very hard for traditional methods to succeed.
The results showed a clear advantage for the genetic sequencing method. When the researchers compared the two approaches, the new sequencing technique identified the specific disease-causing germs in nearly 57 percent of the patients, while the traditional tests only found them in 44 percent. This difference was statistically significant, meaning it was unlikely to be a random chance. The sequencing method proved particularly powerful when the sample came from pus, where it identified the cause in 95 percent of cases, and it also performed better than traditional methods when testing blood and fluid from the lungs. Perhaps most importantly, the new method found a much wider variety of germs. It detected rare and unusual organisms, such as specific types of bacteria that cause tick-borne diseases and others that are difficult to grow in a lab, which the traditional tests completely missed. These rare findings were not just technical curiosities; in several cases, identifying these specific germs allowed doctors to switch to the correct medication, leading to rapid recovery for patients who were not getting better with standard treatment.
The study also looked for clues that could help doctors decide when to order this expensive test. They found that patients with higher levels of a specific protein in their blood, called procalcitonin, were more likely to have a positive result from the sequencing test. This suggests that the level of this protein could serve as a guide to help select the right patients for the test. Furthermore, the research confirmed that the new method works well even when patients have already taken antibiotics, a major limitation of traditional culture methods. The sequencing technology detects the genetic material of the germs, which remains even after the bacteria have been killed by medicine, allowing doctors to identify the enemy even after the battle has begun.
However, the researchers were careful to note that the new tool is not a magic wand that replaces all other methods. In more than half of the cases, the results led to a change in treatment or confirmed the current plan, but in the remaining cases, the test did not immediately alter management. This often happened because the doctors were already treating the patient correctly with broad-spectrum antibiotics, or because the test found germs that were not actually causing the illness. The study also observed that patients whose treatment was guided by the test results stayed in the hospital longer and incurred higher costs, but the researchers explained that this was likely because these patients were sicker and had more complex infections to begin with, not because the test itself made them stay longer. The findings suggest that the best use of this technology is to target it toward patients with severe fevers, high levels of inflammation, or those who have already taken antibiotics without getting better. By combining the power of genetic sequencing with careful clinical judgment, doctors can improve their ability to find the true cause of infectious fevers and use antibiotics more wisely, ensuring that the right treatment reaches the right patient at the right time.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.